M P Hacker
Overview
Explore the profile of M P Hacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chou K, Krapcho A, Hacker M
Biochem Pharmacol
. 2001 Nov;
62(10):1337-43.
PMID: 11709193
The anthrapyrazoles have entered clinical trials and show significant activity against breast cancer. However, these drugs are cardiotoxic and ineffective in multidrug-resistant (MDR) tumor cells. We have reported previously on...
2.
Shreeve S, Sreedharan S, Hacker M, Gannon D, Morgan M
Biochem Biophys Res Commun
. 2000 Jun;
272(3):922-8.
PMID: 10860852
We have characterized vasoactive intestinal peptide (VIP) receptor/G-protein coupling in rat alveolar macrophage (AM) membranes and find that pertussis toxin treatment and antisera against G(alphai3) and G(alphas) reduce high-affinity (125)I-VIP...
3.
Krapcho A, Haydar S, Hacker M, Menta E, Beggiolin G
Bioorg Med Chem Lett
. 2000 Mar;
10(3):305-8.
PMID: 10698460
The synthesis of 1- and 2-substituted aza-benzothiopyranoindazoles has been accomplished. The comparisons of the in vitro antitumor activities of the 2-substituted analogues with the benzothiopyranoindazole chemotypes indicate that the positioning...
4.
Bhushan A, Hacker M, Tritton T
Braz J Med Biol Res
. 1999 Aug;
32(7):827-33.
PMID: 10454740
Resistance to anticancer drugs is a major cause of failure of many therapeutic protocols. A variety of mechanisms have been proposed to explain this phenomenon. The exact mechanism depends upon...
5.
Hazlehurst L, Foley N, Hacker M, Cress A, Greenberger L, de Jong M, et al.
Cancer Res
. 1999 Mar;
59(5):1021-8.
PMID: 10070958
Selection for in vitro drug resistance can result in a complex phenotype with more than one mechanism of resistance emerging concurrently or sequentially. We examined emerging mechanisms of drug resistance...
6.
Krapcho A, Menta E, Oliva A, Di Domenico R, Fiocchi L, Maresch M, et al.
J Med Chem
. 1999 Jan;
41(27):5429-44.
PMID: 9876113
The synthesis and antitumor evaluation of 2, 5-disubstituted-indazolo[4,3-gh]isoquinolin-6(2H)-ones (9-aza-APs) are described. The key intermediates in the synthesis are benz[g]isoquinoline-5,10-diones which are substituted at positions 6 and 9 with groups of...
7.
Bhushan A, Kupperman J, Stone J, Kimberly P, Calman N, Hacker M, et al.
Immunol Cell Biol
. 1998 Sep;
76(4):350-6.
PMID: 9723776
It is demonstrated that methotrexate/cisplatin-sensitive L1210 cells express low levels of major histocompatibility complex (MHC) class II relative to the high levels expressed on methotrexate (MTX)/cisplatin-resistant L1210/DDP cells. L1210 cells...
8.
Quinlan T, Berube K, Hacker M, Taatjes D, Timblin C, Goldberg J, et al.
Free Radic Biol Med
. 1998 May;
24(5):778-88.
PMID: 9586808
To evaluate the contribution of reactive nitrogen species to inflammation by asbestos, Fischer 344 rats were exposed to crocidolite or chrysotile asbestos by inhalation to determine whether increases occurred in...
9.
Xuan Y, Hacker M, Tritton T, Bhushan A
Oncol Rep
. 1998 Apr;
5(2):419-21.
PMID: 9468571
We have previously shown that methotrexate (MTX) transport is impaired in murine L1210 cells selected for cisplatin (DDP) resistance (L1210/DDP) and that the decreased MTX uptake may be due to...
10.
Shreeve S, Hacker M, Gannon D, Kermode J
Ann N Y Acad Sci
. 1996 Dec;
805:516-20.
PMID: 8993433
No abstract available.